The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.
10.5468/ogs.2017.60.5.433
- Author:
Young Jae LEE
1
;
Yong Man KIM
;
Shin Wha LEE
;
Jeong Yeol PARK
;
Dae Yeon KIM
;
Dae Shik SUH
;
Jong Hyeok KIM
;
Young Tak KIM
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. amcymkim@gmail.com
- Publication Type:Original Article
- Keywords:
Liposomal doxorubicin;
Drug therapy;
Hand-foot syndrome
- MeSH:
Anemia;
Asian Continental Ancestry Group;
Carboplatin*;
Disease Progression;
Disease-Free Survival;
Doxorubicin*;
Drug Therapy;
Fallopian Tubes*;
Female;
Hand-Foot Syndrome;
Humans;
Hypersensitivity;
Incidence;
Mucositis;
Neutropenia;
Ovarian Neoplasms;
Retrospective Studies
- From:Obstetrics & Gynecology Science
2017;60(5):433-439
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) with or without carboplatin in Korean patients with recurrent ovarian cancer (ROC), fallopian tube, or primary peritoneal cancer. METHODS: This retrospective study included 52 patients with ROC, fallopian tube, or primary peritoneal cancer who received PLD (50 mg/m²) between 1(st) December 2014 and 31(th) July 2016. RESULTS: The mean number of chemotherapy cycles was 3.8 (range, 2 to 9) in the PLD monotherapy group and 7 (range, 2 to 13) in the PLD combined with carboplatin (PLD-C) group. In overall response rates and clinical beneficial rates, PLD monotherapy group shows 5.0% and 17.5%, and PLD-C group shows 33.3% and 75.0%. The mean progression-free survival (PFS) was 5 and 13 months in the PLD monotherapy and PLD-C groups, respectively. At 6 months after treatment initiation, absence of disease progression was confirmed in 6 (15%) and 10 (83.3%) patients in the PLD monotherapy and PLD-C groups. Hematological adverse events (e.g., neutropenia and thrombocytopenia) were more common in the PLD-C group (P<0.001, P=0.004). The incidence of anemia and non-hematological adverse events, including mucositis, hand-foot syndrome, and allergic reactions, was similar in both groups. CONCLUSION: This study demonstrated the efficacy and safety of PLD monotherapy and PLD-C combination in Korean patients with ROC. This study would be helpful to consider the degree of worry about side effects and treatment expectations after treatment. Further retrospective studies with larger samples are required to confirm the efficacy of PLD monotherapy in Asian patients with platinum-resistant ROC.
